JP2002531137A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531137A5
JP2002531137A5 JP2000586938A JP2000586938A JP2002531137A5 JP 2002531137 A5 JP2002531137 A5 JP 2002531137A5 JP 2000586938 A JP2000586938 A JP 2000586938A JP 2000586938 A JP2000586938 A JP 2000586938A JP 2002531137 A5 JP2002531137 A5 JP 2002531137A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000586938A
Other languages
Japanese (ja)
Other versions
JP4240818B2 (ja
JP2002531137A (ja
Filing date
Publication date
Priority claimed from US09/209,916 external-priority patent/US6358703B1/en
Application filed filed Critical
Publication of JP2002531137A publication Critical patent/JP2002531137A/ja
Publication of JP2002531137A5 publication Critical patent/JP2002531137A5/ja
Application granted granted Critical
Publication of JP4240818B2 publication Critical patent/JP4240818B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000586938A 1998-12-10 1999-12-08 第ｖｉｉｉ因子のための発現系 Expired - Lifetime JP4240818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
US09/209,916 1998-12-10
PCT/US1999/029169 WO2000034505A1 (en) 1998-12-10 1999-12-08 Expression system for factor viii

Publications (3)

Publication Number Publication Date
JP2002531137A JP2002531137A (ja) 2002-09-24
JP2002531137A5 true JP2002531137A5 (enExample) 2005-11-17
JP4240818B2 JP4240818B2 (ja) 2009-03-18

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586938A Expired - Lifetime JP4240818B2 (ja) 1998-12-10 1999-12-08 第ｖｉｉｉ因子のための発現系

Country Status (26)

Country Link
US (10) US6358703B1 (enExample)
EP (1) EP1137797B1 (enExample)
JP (1) JP4240818B2 (enExample)
KR (1) KR100616028B1 (enExample)
AT (1) ATE412765T1 (enExample)
AU (1) AU761801B2 (enExample)
BG (1) BG65431B1 (enExample)
BR (1) BRPI9916069B8 (enExample)
CA (1) CA2354845C (enExample)
CZ (1) CZ302330B6 (enExample)
DE (1) DE69939839D1 (enExample)
DK (1) DK1137797T3 (enExample)
ES (1) ES2315026T3 (enExample)
HU (1) HU228489B1 (enExample)
IL (2) IL143353A0 (enExample)
NO (1) NO329544B1 (enExample)
NZ (1) NZ512234A (enExample)
PL (1) PL200676B1 (enExample)
PT (1) PT1137797E (enExample)
RO (1) RO121604B1 (enExample)
RU (1) RU2249041C2 (enExample)
SI (1) SI20644B (enExample)
SK (1) SK286945B6 (enExample)
TR (1) TR200101592T2 (enExample)
UA (1) UA77383C2 (enExample)
WO (1) WO2000034505A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1460131A3 (en) * 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
AU2004215912B2 (en) * 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US7709224B2 (en) * 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP2008518597A (ja) * 2004-10-29 2008-06-05 セントカー・インコーポレーテツド 化学的規定培地組成物
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
TWI423986B (zh) 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
KR101005967B1 (ko) * 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
CA2728708A1 (en) * 2008-06-25 2009-12-30 Bayer Healthcare Llc Factor viii muteins with reduced immunogenicity
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
KR101691443B1 (ko) * 2008-09-03 2016-12-30 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
KR101980164B1 (ko) * 2011-05-13 2019-05-20 옥타파마 아게 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
HRP20221531T1 (hr) * 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
WO2018017923A1 (en) 2016-07-22 2018-01-25 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
JPH0788399B2 (ja) * 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
DE3769872D1 (de) * 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.
EP0260148A3 (en) 1986-09-12 1989-06-07 Genentech, Inc. Improved recombinant expression method, vector and transformed cells
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
AU656720B2 (en) * 1989-12-01 1995-02-16 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
EP0629700A3 (en) * 1993-06-10 1995-02-15 Miles Inc Mammalian vector and cell lines that have increased productivity.
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus

Similar Documents

Publication Publication Date Title
BE2018C020I2 (enExample)
BE2015C057I2 (enExample)
BE2016C007I2 (enExample)
BE2015C018I2 (enExample)
BE2014C017I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
JP2002509754A5 (enExample)
BRPI0017527B8 (enExample)
JP2002516484A5 (enExample)
BRPI0001672A2 (enExample)
JP2002531933A5 (enExample)
BRPI0001542A2 (enExample)
JP2002531527A5 (enExample)
BRPI0012675B8 (enExample)
JP2001055402A5 (enExample)
JP2002519235A5 (enExample)
BRPI0017522A2 (enExample)
HU0004776D0 (enExample)
JP2002518167A5 (enExample)
IN188930B (enExample)
JP2002527268A5 (enExample)
BRMU7902607U2 (enExample)
BRPI9917761A2 (enExample)